About
HQL Pharmaceuticals' mission is to transform drug discovery into a computationally driven, highly efficient process, yielding a large diversity of high-quality drug candidates and address the challenges associated with scaffold hopping, antagonizing proteinprotein interactions, hitting two targets at the same time, and transforming fragment hits into viable drug candidates. HQL's ChemSpace Scanner (CSS) computational platform enables the combinationof multiple drug design algorithms and approaches and enables screening of huge (order of magnitude >1030) chemical libraries against high-resolution, high-information-content models. The CSS platform consists of digitized chemical libraries, a screening algorithm,a drug model (against which the virtual library is screened), and tools for scoring and ranking resulting hits. In 2014, HQL Pharmaceuticals and Viva Biotech Ltd of Shaghai, China, entered into a strategic alliance to jointly provide drug discovery services.